CRDF Cardiff Oncology
- 3.380
- +0.180+5.63%
Cardiff Oncology News
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...
HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $14 price target.
Cardiff Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 300% HC Wainwright & Co. → $14 Reiterates Buy → Buy 03/06/2024 300% HC Wainwright & Co. $12 → $
Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
Earnings Call Summary | Cardiff Oncology(CRDF.US) Q1 2023 Earnings Conference
The following is a summary of the Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript:Financial Performance:Cardiff Oncology reported a total of $67.2 million in cash and short-term investm
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call Transcript
AEON Biopharma, Allarity Therapeutics, ModivCare Among Healthcare Movers
Cardiff Oncology (CRDF) Gets a Buy From Piper Sandler
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersHelius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. The company's market cap stands at $3.5 million. Vaxxinity (NASDAQ:VAXX) shares moved up
Cardiff Oncology Shares Are Trading Lower. The Company Reported Q1 Financial Results.
Cardiff Oncology Shares Are Trading Lower. The Company Reported Q1 Financial Results.
Cardiff Oncology (CRDF.US): The 2024 Q1 financial report achieved revenue of US$205,000, with a previous value of US$83,000, with an expected value of US$50,000; earnings per share of -0.22 dollars, previous value of -0.25 dollars, expected value of -0.25
Cardiff Oncology (CRDF.US): The 2024 Q1 financial report achieved revenue of US$205,000, with a previous value of US$83,000, with an expected value of US$50,000; earnings per share of -0.22 dollars, previous value of -0.25 dollars, expected value of -0.25 dollars.
Cardiff Oncology Q1 2024 GAAP EPS $(0.22) Beats $(0.25) Estimate, Sales $205.000K Beat $55.000K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 12 percent increase over losses of $(0.25) p
Cardiff Oncology 1Q Loss/Shr 22c >CRDF
Cardiff Oncology 1Q Loss/Shr 22c >CRDF
Press Release: Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update - In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage
Cardiff Oncology Reveals Latest Cancer Research at AACR
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 That Supports Ongoing First-line RAS-mutated MCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersHeron Therapeutics (NASDAQ:HRTX) shares rose 35.4% to $3.19 during Wednesday's regular session. The market value of their outstanding shares is at $479.4 million. The company's, Q4 earnings cam
Analysis
Price Target
No Data
